EpiCARE is the European Reference Network for all rare and complex epilepsies. The ERNs, launched in 2017, aim to improve care for rare diseases, reduce inequalities in access to the best diagnostic, treatment practices and investigational tools. They involve more than 900 highly specialised health care teams.
The ERN is composed by 61 medical teams of experts, accredited by their respective national authorities and the European Commission. It is present in 24/27 EU countries and in Norway. Supporting medical teams are present in Bulgaria, Greece, Ireland, Switzerland and in the UK.
In October 2023, the administrative coordination of EpiCARE was entrusted to the Hospital Sant Joan de Déu in Barcelona, under the leadership and coordination of Professor Dr. Alexis Arzimanoglou.
The deadline for EPNS Research Meeting 2026 abstract submissions is 23 March 2026, and it will not be extended.
The meeting will take place on 16–17 October 2026 at The MET Hotel in Thessaloniki, Greece. It brings together paediatric neurology researchers at all career stages and provides an excellent opportunity to present and discuss new research in the field.
On the occasion of Rare Disease Day (28 February 2026), DG SANTE has prepared these interesting materials, which you can find at the following link.
At the occasion of the International Epilepsy Day on Monday February 9th, we invite you to listen to the interview Pr. Arzimanoglou, Coordinator of the European Reference Network for Rare and Complex epilepsies gave to the International League Against Epilepsy (ILAE) focusing on how EpiCARE, funded by the European Commission, contributes to better care for patients suffering from epilepsy.
📢 You can now request a certificate of attendance after registering for and attending the webinar! Please email the EpiCARE Helpdesk afterward, and we’ll send it to you: [email protected]
The Genetic Research workgroup is sharing opportunities of collaborative calls for European series of patients carrying variants in already known genes, to facilitate this type of studies by connecting several centers across Europe involved in the study of genetic epilepsies.
Have a look at the calls for collaborative genetic research here, and contact Sébile Tchaicha, Research project manager, if you have any question !
to regularly update neurologists and child neurologists on the best practices in epilepsy treatment.
A disease is defined as rare when it affects fewer than one in 2.000 people, is serious, chronic and often life-threatening. Between 5.000 and 8.000 of rare diseases affect daily life of around 30 million people in the EU.
The ERN EpiCARE brings together highly specialized health centres (38 full members and 12 affiliated partners) in 26 European countries with expertise in rare and complex epilepsies. If you are a healthcare professional and would like to refer a patient to us, or if you are a patient yourself, or a family member of a patient, please get in touch via our contact page.
The rare disease community comes together in calling on the EU institutions and our national governments to stand by the European Reference Networks, and to uphold their commitment to enable long-lasting impact in people’s lives and, fundamentally, give all people living with a rare or complex condition in Europe the same opportunities to access timely and adequate specialised healthcare. Read the open letter from the rare disease community here
Accessibility
To improve accessibility of detailed diagnostics to individuals of all ages with rare and complex epilepsies across Europe, including clinical evaluation and investigation.
Developing treatment
To develop treatment protocols and monitor standardised outcomes of rare and complex epilepsies.
Awareness
To improve awareness and accessibility to protocols for physicians and individuals with rare and complex epilepsies across Europe for treatment.
Education
To enhance educational activities and training opportunities across Europe by interchange across the network.
Collaborative research
To enhance opportunities for registries, and collaborative research for the benefit of individuals with rare and complex epilepsies across Europe.